Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT01912963
Brief Title: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

First Submitted : July 24, 2013
First Submitted that Met QC Criteria : July 29, 2013
First Posted : July 31, 2013 (Estimate)

Results First Submitted : October 8, 2018
Results First Submitted that Met QC Criteria : November 9, 2018
Results First Posted : December 5, 2018

Last Update Submitted that Met QC Criteria : November 9, 2018
Last Update Posted : December 5, 2018